Beranda › Sarkoma Jaringan Lunak › Texas
Uji klinis Sarkoma Jaringan Lunak di Texas
38 studi untuk Sarkoma Jaringan Lunak mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07189871Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- UT MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06498648A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
Menerima pesertaFase 1/2
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04094610DESTINY-PANTUMOUR04
- Research Site, Dallas
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000Anti-GD2 ADC M3554 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06641908A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07705334First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
- University Of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06797999Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05732831Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- UT MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 12 hingga 85 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03715933Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- UT MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05711615A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06760819Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05334069Actinium Therapy for Late-stage Aggressive Sarcomas
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07156565STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
- NEXT Dallas, Irving
- dan 2 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06975293Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT01772771Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07283731T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06474676Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Ut Southwestern Medical Center, Dallas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07139990A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06242470Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- M D Anderson Cancer Center, Houston
Menerima peserta
Usia 10 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT04199026A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- The University of Texas M. D. Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07444619IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06910657Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- MD Anderson Cancer Center, Houston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT07377747Lead-212 PSV359 Therapy for Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06710756Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- M D Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT04771520A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT06789172A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
- The University of Texas M. D. Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT07049848Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
- M.D. Anderson Children's Cancer Hospital, Houston
Menerima pesertaFase 2
Usia 8 hingga 30 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT05726383Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
- William Beaumont Army Medical Center, Fort Bliss
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT06129903A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT04969835Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04693377Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Children's Health Dallas, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 2 hingga 30 · Semua jenis kelamin · Diperbarui 3 Feb 2026 · NCT05734066HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
Menerima pesertaFase 1
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 22 Jan 2026 · NCT04995003cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT04370587BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Feb 2025 · NCT06272864Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.